01/08/2026
Liposomal doxorubicin has been on the market for over two decades, yet very few manufacturers worldwide have successfully brought its production in-house. The formulation chemistry is well documented in the literature — but the real barrier has never been the theory. It’s the practical ex*****on: batch-to-batch consistency, encapsulation efficiency that holds up at scale, and the dozens of small process decisions that only come from having actually run the process.
At Nanodorf, we’ve built that practical, hands-on manufacturing expertise for the established liposomal doxorubicin process — and we work with manufacturers who want to shortcut the trial-and-error phase: documentation, batch records, analytical methods, and on-site training to get a working process running on your own equipment.
If your team is evaluating local production of complex injectables — particularly where local-content requirements are shaping procurement decisions — this is a conversation worth having.
Follow along — we’ll be sharing more on what actually determines manufacturing success for complex generics like this one.
